Judy Garber

Judy Garber contributed to the OlympiA trial demonstrating adjuvant olaparib benefit for BRCA1/2-mutated HER2-negative early breast cancer with residual risk, establishing PARP inhibition as an adjuvant strategy. Her work bridges hereditary cancer genetics with treatment implications in the neoadjuvant and adjuvant settings for BRCA carriers. She leads the Cancer Genetics and Prevention program at Dana-Farber and has contributed to guidelines for BRCA-mutated breast cancer management. Garber is a founding contributor to the field of hereditary breast and ovarian cancer syndrome clinical management.